Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies

• Published in: Cancer Vol. 130; no. 3; pp. 400 - 409
• Main Authors: Knisely, Anne, Ahmed, Jibran, Stephen, Bettzy, Piha‐Paul, Sarina A., Karp, Daniel, Zarifa, Abdulrazzak, Fu, Siqing, Hong, David Sanghyun, Rodon Ahnert, Jordi, Yap, Timothy A., Tsimberidou, Apostolia M., Alshawa, Anas, Dumbrava, Ecaterina E., Yang, Yali, Song, Juhee, Meric‐Bernstam, Funda, Jazaeri, Amir A., Naing, Aung
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.02.2024
• Subjects: Agonists; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Cancer; Cervical cancer; Criteria; Disease control; Effectiveness; Endometrial cancer; Female; Genital Neoplasms, Female - drug therapy; Humans; immune checkpoint blockade; Immune checkpoint inhibitors; Immunoglobulin G; Immunotherapy; Malignancy; Monoclonal antibodies; Neoplasm Recurrence, Local - pathology; Ovarian cancer; Radiation therapy; Safety; Solid tumors; Survival; Targeted cancer therapy; Tumor necrosis factor; Tumors; Uterine cancer; Uterine Cervical Neoplasms - drug therapy; endometrial cancer; ovarian cancer; cervical cancer; immunotherapy; immune checkpoint blockade

Background Immune checkpoint blockade has shown mixed results in advanced/recurrent gynecologic malignancies. Efficacy may be improved through costimulation with OX40 and 4‐1BB agonists. The authors sought to evaluate the safety and efficacy of avelumab combined with utomilumab (a 4‐1BB agonist), PF...